← Back to Patent Explorer
US4338319A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for the treatment of chronic obstructive airway or cardiac diseases

Assignee: Draco AB
•
Filing: 1980-11-21
•
Granted: 1982-07-06
•
Expires: 2000-11-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for the treatment of chronic obstructive airway disease or cardiac disease by administration 3-ethylxantine or a pharmaceutically acceptable salt thereof; a pharmaceutical preparation containing 3-ethylxanthine.

Inventors

  • 👤 Per G. Kjellin
  • 👤 Carl G. A. Persson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 16:51
CPC Classifications
C; C07; C07D; C07D473/00; C07D473/02; C07D473/04; C07D473/06

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 33 words
A method for the treatment of chronic obstructive airway disease treatable by theophylline therapy, characterized in administering to a host suffering therefrom a therapeutically active dose of a compound of the formula ##STR3##
Claim 2
Independent Claim 33 words
A method for the treatment of chronic obstructive airway disease treatable by theophylline therapy, characterized in administering to a host suffering therefrom a therapeutically active dose of a compound of the formula ##STR3##
Claim 3
Independent Claim 37 words
A method for the treatment of cardiac disease treatable by theophylline therapy, characterized in administering to a host suffering therefrom a therapeutically active dose of a compound of the formula ##STR4## or a pharmaceutically acceptable salt thereof.
Claim 4
Independent Claim 37 words
A method for the treatment of cardiac disease treatable by theophylline therapy, characterized in administering to a host suffering therefrom a therapeutically active dose of a compound of the formula ##STR4## or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim 30 words
A method according to claim 1 or 2 comprising oral administration dosages of 100-2000 mg of a compound of the formula I or a pharmaceutically acceptable salt thereof 1-4 times/day.

References Cited (Backward Citations)

GB683523A Cited
US2767182A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-07-05 1986-01-04 1986-07-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-07-05 1990-01-04 1990-07-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-07-05 1994-01-04 1994-07-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag